Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Teva-Kowa Venture Plans Expansion In Japan’s Generics Market

This article was originally published in PharmAsia News

Executive Summary

Israel's Teva Pharmaceutical Industries plans to expand its presence in Japan through its new joint venture with Kowa Pharma. With a planned investment of more than $110.7 million by 2015, Teva hopes to bring more than 200 generic drugs to the Japanese market, mainly for treating cancer, cholesterol and high blood pressure. With the expansion, the Teva-Kowa venture plans to add about 400 workers and take charge of 40 Teva generics already on the market. Teva-Kowa's president said the venture also will seek friendly partnerships, mergers and acquisitions so it can have 10 percent of the generics market. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel